Form 8-K ALBANY MOLECULAR RESEARC For: Jan 12

�

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

�

�

FORM 8-K

�

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

�

Date of Report (Date of earliest event reported): January 12, 2015

�

ALBANY MOLECULAR RESEARCH, INC.

(Exact Name of Registrant as Specified in Charter)

�

Delaware	�	000-25323	�	14-1742717
(State or other jurisdiction	�	(Commission	�	(IRS Employer
of incorporation)	�	File Number)	�	Identification No.)

�

26 Corporate Circle, Albany, NY	�	12212
(Address of principal executive offices)	�	(Zip Code)

�

Registrant’s telephone number, including area code: (518) 512-2000

�

�(Former name or former address, if changed since last report)

�

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below) :

�

� Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

�

� Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

�

� Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

�

� Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

�

�

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

�

On January 12, 2015, Albany Molecular Research, Inc. (the “ Company ”) issued a press release (the “ Press Release ”) announcing that Felicia Ladin, 42, has been appointed by the Board of Directors as the Senior Vice President, Chief Financial Officer and Treasurer of the Company, such appointment to be effective on February 4, 2015. Ms. Ladin will report to the President and Chief Executive Officer of the Company.

�

Ms. Ladin was most recently Senior Vice President, CFO, Global Specialty Medicines at Teva Pharmaceuticals, USA (“Teva”). Prior to that, Ms. Ladin held positions of increasing responsibility directing Teva’s financial planning and analysis operations and was tax director. During her 12 year tenure at Teva, Ms. Ladin was instrumental in developing and implementing financial systems and infrastructure through a number of acquisitions, and driving consistency and efficiencies across locations, supporting the Specialty Medicine division’s growth into an $8 billion global business. Ms. Ladin received her M.S. in Taxation from Seton Hall University and a B.S. in Accounting from The University of Delaware.

�

The Press Release also announced that Mr. Michael M. Nolan, the Senior Vice President, Chief Financial Officer and Treasurer of the Company, will be terminating his service under those offices effective on February 4, 2015.� Mr. Nolan will remain employed by the Company through February 2015 to support an orderly transition.

�

A copy of the press release announcing these events is attached hereto as Exhibit 99.1 and is furnished herewith.

�

Item 9.01.

Financial Statements and Exhibits.

�

(d) Exhibits

�

Exhibit No.	�	Description
�	�	�
99.1	�	Press Release dated January 12, 2015.

�

�

SIGNATURES

�

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

�

Date: January 15, 2015	ALBANY MOLECULAR RESEARCH, INC.
�	�	�
�	By:	/s/ Lori M. Henderson
�	�	Name: Lori M. Henderson
�	�	Title:� Senior Vice President and General Counsel

�

�

EXHIBIT INDEX

�

Exhibit	�	�
No.	�	Description�
�	�	�
99.1	�	Press Release dated January 12, 2015.

�

�

Exhibit 99.1

�

AMRI Appoints Felicia Ladin Senior Vice President, Chief Financial Officer and Treasurer

�

Albany, NY (January 12, 2015) – AMRI (NASDAQ: AMRI) today announced that Michael M. Nolan, senior vice president and chief financial officer, will be departing AMRI. Mr. Nolan will remain with AMRI through February 2015 to support an orderly transition.

�

The company also announced that Felicia Ladin will join the company in the same role, effective February 4, 2015. “We appreciate Mike’s contributions to AMRI's growth, and I know I speak for the management team and Board of Directors in wishing him success with his future endeavors,” said William S. Marth, AMRI’s President and Chief Executive Officer.�

�

“I am pleased that Felicia will be joining the AMRI team at this important time for the company,” continued Mr. Marth. “As we continue to build and integrate our business, Felicia’s strong track record of building global finance infrastructures and teams will be a tremendous addition to AMRI.”

�

Ms. Ladin brings more than 20 years of finance, accounting and tax management experience to AMRI. A CPA by training, Ladin has spent the majority of her career in the pharmaceutical industry, most recently as Senior Vice President, CFO, Global Specialty Medicines at Teva Pharmaceuticals, USA. Between 2008 and 2014, Ms. Ladin held positions of increasing responsibility directing Teva’s financial planning and analysis operations, and from 2002 to 2008 was tax director for the U.S. During her 12 year tenure at Teva, Ladin was instrumental in developing and implementing financial systems and infrastructure through a number of acquisitions, and driving consistency and efficiencies across locations, supporting the Specialty Medicine division’s growth into an $8 billion global business.

�

The company intends to release its fourth quarter and full year 2014 financial results and 2015 guidance, including the most recent acquisitions, in February 2015.

�

About AMRI

Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), and Drug Product Manufacturing. Our DDS segment provides comprehensive services from hit identification to IND, including expertise with diverse chemistry, library design and synthesis, in vitro biology and pharmacology, drug metabolism and pharmacokinetics, as well as natural products. API Manufacturing supports the chemical development and cGMP manufacture of complex API, including potent, controlled substances, biologics, peptides, steroids, and cytotoxic compounds. Drug Product Manufacturing supports pre-clinical through commercial scale production of complex liquid-filled and lyophilized parenteral formulations. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).

�

Contacts:
Investors: Patty Eisenhaur, AMRI Investor Relations, 518-512-2936
Media: Gina Rothe, AMRI Communications, 518-512-2512

�

�

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• AM Best Affirms Credit Ratings of Symetra Financial Corporation and Its Subsidiaries
• Energy Harvesting System Market Poised for Remarkable Growth, Projected to Reach USD 1317.56 Million by 2031
• GradEx 109 – Toronto’s largest free art and design exhibition returns May 1 to 5